Bristol-Myers, Celgene to redeem 4% notes, 3.25% notes due 2023

By Taylor Fox

New York, Feb. 22 – Bristol-Myers Squibb Co. plans to redeem all of its 4% notes due 2023 (Cusips: 110122DA3, 110122BL1) that remain outstanding following the early settlement of its tender offers and $42.25 million of its $932,101,000 outstanding 3.25% notes due 2023 (Cusips: 110122BK3, U11009AK0), according to a news release.

Bristol-Myers wholly-owned subsidiary Celgene Corp. will also redeem its 4% notes due 2023 (Cusip: 151020AJ3) and 3.25% notes due 2023 (Cusip: 151020BA1).

The notes will be redeemed at the make-whole redemption prices plus interest.

The two 4% note series will be redeemed on March 24 and the two 3.25% note series will be redeemed March 9.

The Bank of New York Mellon is the trustee.

The biopharmaceutical company is based in New York.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.